Seclidemstat (SP-2577) is a potent, oral, bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with an IC50 value of 13 nM. Seclidemstat (SP-2577) has potential antitumor activity.

 

Brand: BCM

 

Target: LSD1:127 nM

 

Signaling Pathways: Chromatin/Epigenetic

 

In Vitro: The combination therapy of Seclidemstat (SP-2577) with checkpoint inhibitors may induce or augment immunogenic responses of SWI/SNF-mutated ovarian cancers. Seclidemstat promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) cell lines. Seclidemstat (3 μM) promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line.

 

pKa: 7.96±0.43(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; 

 

Isomeric SMILES: C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O  

 

InChIKey: MVSQDUZRRVBYLA-HYARGMPZSA-N  

 

InChI: InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+

 

Attribute
[Chem Name]	N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
[Synonym]	Seclidemstat; SP-2577
[CAS No.]	1423715-37-0
[MDL No.]	MFCD31630770
[Formula]	C20H23ClN4O4S
[Molecular]	450.94
[Form]	Solid powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag